BCG vaccination and tuberculosis in Japan

J Epidemiol. 2003 May;13(3):127-35. doi: 10.2188/jea.13.127.

Abstract

This paper summarizes Bacillus Calmette-Guerin (BCG) vaccination and revaccination policies in Japan, its cost-effectiveness, side effects, proposed selective vaccination strategy, and present tuberculosis situation in Japanese perspectives based on Medline database and other published reports. Universal BCG vaccination in infants and revaccination among children were not found economically justifiable. Overall tuberculosis incidence in Japan is higher than that of other developed countries. Trend of decline in tuberculosis incidence is similar to that of the countries where universal BCG vaccination has never been implemented. In the recent years, the number of tuberculosis group infection has been escalating. Since BCG revaccination program has already been discontinued, a consensus on universal BCG vaccination is also essential based on social, political, and economical factors. Side by side, more pragmatic strategies such as well-defined tuberculin test, selective vaccination policy based on tuberculosis incidence in each administrative zone, and early vaccination of high risk groups, should be formulated.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Adverse Drug Reaction Reporting Systems
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / adverse effects
  • BCG Vaccine / therapeutic use*
  • Child
  • Child, Preschool
  • Cost-Benefit Analysis
  • Developed Countries / statistics & numerical data
  • Disease Outbreaks / prevention & control*
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Injections / methods
  • Japan / epidemiology
  • Mass Vaccination / economics
  • Mass Vaccination / statistics & numerical data*
  • Treatment Outcome
  • Tuberculosis / epidemiology*

Substances

  • BCG Vaccine